English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessSanofi and GSK launch trial for COVID-19 protein-based vaccine

    Sanofi and GSK launch trial for COVID-19 protein-based vaccine

    Sanofi and GSK said in a joint statement on Thursday they had started the "Phase 1/2" trial for their adjuvanted COVID-19 vaccine, which they hope to make available across the world.

    Reuters
    September 03, 2020 / 11:04 IST

    French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments against the coronavirus pandemic.

    Sanofi and GSK said in a joint statement on Thursday they had started the "Phase 1/2" trial for their adjuvanted COVID-19 vaccine, which they hope to make available across the world.

    This vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines with GSK's established pandemic adjuvant technology.

    Reuters
    first published: Sep 3, 2020 11:02 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347